Report cover image

Global Biologic Medications for Psoriasis Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 119 Pages
SKU # APRC20339546

Description

Summary

According to APO Research, The global Biologic Medications for Psoriasis market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Biologic Medications for Psoriasis include AbbVie Biotechnology, Amgen, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Janssen Biotech, Kyowa Kirin, LEO Pharma and Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Biologic Medications for Psoriasis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologic Medications for Psoriasis.
The Biologic Medications for Psoriasis market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biologic Medications for Psoriasis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Biologic Medications for Psoriasis Segment by Company

AbbVie Biotechnology
Amgen
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb
Eli Lilly
Janssen Biotech
Kyowa Kirin
LEO Pharma
Novartis
Ortho Dermatologics
Pfizer
Samsung Bioepis
Tiefenbacher Pharmaceuticals
UCB
Dalian Yawei Pharmaceutical
Hanwha Chemical
China Medical System
Qilu Pharmaceutical
Biologic Medications for Psoriasis Segment by Type

Interleukin Inhibitors
Tyrosine Kinase Inhibitors
Phosphodiesterase Inhibitors
TNF-α Inhibitors
Other
Biologic Medications for Psoriasis Segment by Application

Retail Pharmacies
Hospital and Clinic
Other
Biologic Medications for Psoriasis Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologic Medications for Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologic Medications for Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologic Medications for Psoriasis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biologic Medications for Psoriasis manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Biologic Medications for Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

119 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Biologic Medications for Psoriasis Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Biologic Medications for Psoriasis Sales Estimates and Forecasts (2020-2031)
1.3 Biologic Medications for Psoriasis Market by Type
1.3.1 Interleukin Inhibitors
1.3.2 Tyrosine Kinase Inhibitors
1.3.3 Phosphodiesterase Inhibitors
1.3.4 TNF-α Inhibitors
1.3.5 Other
1.4 Global Biologic Medications for Psoriasis Market Size by Type
1.4.1 Global Biologic Medications for Psoriasis Market Size Overview by Type (2020-2031)
1.4.2 Global Biologic Medications for Psoriasis Historic Market Size Review by Type (2020-2025)
1.4.3 Global Biologic Medications for Psoriasis Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Biologic Medications for Psoriasis Sales Breakdown by Type (2020-2025)
1.5.2 Europe Biologic Medications for Psoriasis Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Biologic Medications for Psoriasis Sales Breakdown by Type (2020-2025)
1.5.4 South America Biologic Medications for Psoriasis Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Biologic Medications for Psoriasis Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Biologic Medications for Psoriasis Industry Trends
2.2 Biologic Medications for Psoriasis Industry Drivers
2.3 Biologic Medications for Psoriasis Industry Opportunities and Challenges
2.4 Biologic Medications for Psoriasis Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Biologic Medications for Psoriasis Revenue (2020-2025)
3.2 Global Top Players by Biologic Medications for Psoriasis Sales (2020-2025)
3.3 Global Top Players by Biologic Medications for Psoriasis Price (2020-2025)
3.4 Global Biologic Medications for Psoriasis Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Biologic Medications for Psoriasis Major Company Production Sites & Headquarters
3.6 Global Biologic Medications for Psoriasis Company, Product Type & Application
3.7 Global Biologic Medications for Psoriasis Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Biologic Medications for Psoriasis Market CR5 and HHI
3.8.2 Global Top 5 and 10 Biologic Medications for Psoriasis Players Market Share by Revenue in 2024
3.8.3 2023 Biologic Medications for Psoriasis Tier 1, Tier 2, and Tier 3
4 Biologic Medications for Psoriasis Regional Status and Outlook
4.1 Global Biologic Medications for Psoriasis Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Biologic Medications for Psoriasis Historic Market Size by Region
4.2.1 Global Biologic Medications for Psoriasis Sales in Volume by Region (2020-2025)
4.2.2 Global Biologic Medications for Psoriasis Sales in Value by Region (2020-2025)
4.2.3 Global Biologic Medications for Psoriasis Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Biologic Medications for Psoriasis Forecasted Market Size by Region
4.3.1 Global Biologic Medications for Psoriasis Sales in Volume by Region (2026-2031)
4.3.2 Global Biologic Medications for Psoriasis Sales in Value by Region (2026-2031)
4.3.3 Global Biologic Medications for Psoriasis Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Biologic Medications for Psoriasis by Application
5.1 Biologic Medications for Psoriasis Market by Application
5.1.1 Retail Pharmacies
5.1.2 Hospital and Clinic
5.1.3 Other
5.2 Global Biologic Medications for Psoriasis Market Size by Application
5.2.1 Global Biologic Medications for Psoriasis Market Size Overview by Application (2020-2031)
5.2.2 Global Biologic Medications for Psoriasis Historic Market Size Review by Application (2020-2025)
5.2.3 Global Biologic Medications for Psoriasis Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Biologic Medications for Psoriasis Sales Breakdown by Application (2020-2025)
5.3.2 Europe Biologic Medications for Psoriasis Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Biologic Medications for Psoriasis Sales Breakdown by Application (2020-2025)
5.3.4 South America Biologic Medications for Psoriasis Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Biologic Medications for Psoriasis Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 AbbVie Biotechnology
6.1.1 AbbVie Biotechnology Comapny Information
6.1.2 AbbVie Biotechnology Business Overview
6.1.3 AbbVie Biotechnology Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AbbVie Biotechnology Biologic Medications for Psoriasis Product Portfolio
6.1.5 AbbVie Biotechnology Recent Developments
6.2 Amgen
6.2.1 Amgen Comapny Information
6.2.2 Amgen Business Overview
6.2.3 Amgen Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Amgen Biologic Medications for Psoriasis Product Portfolio
6.2.5 Amgen Recent Developments
6.3 Boehringer Ingelheim Pharmaceuticals
6.3.1 Boehringer Ingelheim Pharmaceuticals Comapny Information
6.3.2 Boehringer Ingelheim Pharmaceuticals Business Overview
6.3.3 Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio
6.3.5 Boehringer Ingelheim Pharmaceuticals Recent Developments
6.4 Bristol-Myers Squibb
6.4.1 Bristol-Myers Squibb Comapny Information
6.4.2 Bristol-Myers Squibb Business Overview
6.4.3 Bristol-Myers Squibb Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Bristol-Myers Squibb Biologic Medications for Psoriasis Product Portfolio
6.4.5 Bristol-Myers Squibb Recent Developments
6.5 Eli Lilly
6.5.1 Eli Lilly Comapny Information
6.5.2 Eli Lilly Business Overview
6.5.3 Eli Lilly Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Eli Lilly Biologic Medications for Psoriasis Product Portfolio
6.5.5 Eli Lilly Recent Developments
6.6 Janssen Biotech
6.6.1 Janssen Biotech Comapny Information
6.6.2 Janssen Biotech Business Overview
6.6.3 Janssen Biotech Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Janssen Biotech Biologic Medications for Psoriasis Product Portfolio
6.6.5 Janssen Biotech Recent Developments
6.7 Kyowa Kirin
6.7.1 Kyowa Kirin Comapny Information
6.7.2 Kyowa Kirin Business Overview
6.7.3 Kyowa Kirin Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Kyowa Kirin Biologic Medications for Psoriasis Product Portfolio
6.7.5 Kyowa Kirin Recent Developments
6.8 LEO Pharma
6.8.1 LEO Pharma Comapny Information
6.8.2 LEO Pharma Business Overview
6.8.3 LEO Pharma Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
6.8.4 LEO Pharma Biologic Medications for Psoriasis Product Portfolio
6.8.5 LEO Pharma Recent Developments
6.9 Novartis
6.9.1 Novartis Comapny Information
6.9.2 Novartis Business Overview
6.9.3 Novartis Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Novartis Biologic Medications for Psoriasis Product Portfolio
6.9.5 Novartis Recent Developments
6.10 Ortho Dermatologics
6.10.1 Ortho Dermatologics Comapny Information
6.10.2 Ortho Dermatologics Business Overview
6.10.3 Ortho Dermatologics Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Ortho Dermatologics Biologic Medications for Psoriasis Product Portfolio
6.10.5 Ortho Dermatologics Recent Developments
6.11 Pfizer
6.11.1 Pfizer Comapny Information
6.11.2 Pfizer Business Overview
6.11.3 Pfizer Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Pfizer Biologic Medications for Psoriasis Product Portfolio
6.11.5 Pfizer Recent Developments
6.12 Samsung Bioepis
6.12.1 Samsung Bioepis Comapny Information
6.12.2 Samsung Bioepis Business Overview
6.12.3 Samsung Bioepis Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Samsung Bioepis Biologic Medications for Psoriasis Product Portfolio
6.12.5 Samsung Bioepis Recent Developments
6.13 Tiefenbacher Pharmaceuticals
6.13.1 Tiefenbacher Pharmaceuticals Comapny Information
6.13.2 Tiefenbacher Pharmaceuticals Business Overview
6.13.3 Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio
6.13.5 Tiefenbacher Pharmaceuticals Recent Developments
6.14 UCB
6.14.1 UCB Comapny Information
6.14.2 UCB Business Overview
6.14.3 UCB Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
6.14.4 UCB Biologic Medications for Psoriasis Product Portfolio
6.14.5 UCB Recent Developments
6.15 Dalian Yawei Pharmaceutical
6.15.1 Dalian Yawei Pharmaceutical Comapny Information
6.15.2 Dalian Yawei Pharmaceutical Business Overview
6.15.3 Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Product Portfolio
6.15.5 Dalian Yawei Pharmaceutical Recent Developments
6.16 Hanwha Chemical
6.16.1 Hanwha Chemical Comapny Information
6.16.2 Hanwha Chemical Business Overview
6.16.3 Hanwha Chemical Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Hanwha Chemical Biologic Medications for Psoriasis Product Portfolio
6.16.5 Hanwha Chemical Recent Developments
6.17 China Medical System
6.17.1 China Medical System Comapny Information
6.17.2 China Medical System Business Overview
6.17.3 China Medical System Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
6.17.4 China Medical System Biologic Medications for Psoriasis Product Portfolio
6.17.5 China Medical System Recent Developments
6.18 Qilu Pharmaceutical
6.18.1 Qilu Pharmaceutical Comapny Information
6.18.2 Qilu Pharmaceutical Business Overview
6.18.3 Qilu Pharmaceutical Biologic Medications for Psoriasis Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Qilu Pharmaceutical Biologic Medications for Psoriasis Product Portfolio
6.18.5 Qilu Pharmaceutical Recent Developments
7 North America by Country
7.1 North America Biologic Medications for Psoriasis Sales by Country
7.1.1 North America Biologic Medications for Psoriasis Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Biologic Medications for Psoriasis Sales by Country (2020-2025)
7.1.3 North America Biologic Medications for Psoriasis Sales Forecast by Country (2026-2031)
7.2 North America Biologic Medications for Psoriasis Market Size by Country
7.2.1 North America Biologic Medications for Psoriasis Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Biologic Medications for Psoriasis Market Size by Country (2020-2025)
7.2.3 North America Biologic Medications for Psoriasis Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Biologic Medications for Psoriasis Sales by Country
8.1.1 Europe Biologic Medications for Psoriasis Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Biologic Medications for Psoriasis Sales by Country (2020-2025)
8.1.3 Europe Biologic Medications for Psoriasis Sales Forecast by Country (2026-2031)
8.2 Europe Biologic Medications for Psoriasis Market Size by Country
8.2.1 Europe Biologic Medications for Psoriasis Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Biologic Medications for Psoriasis Market Size by Country (2020-2025)
8.2.3 Europe Biologic Medications for Psoriasis Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Biologic Medications for Psoriasis Sales by Country
9.1.1 Asia-Pacific Biologic Medications for Psoriasis Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Biologic Medications for Psoriasis Sales by Country (2020-2025)
9.1.3 Asia-Pacific Biologic Medications for Psoriasis Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Biologic Medications for Psoriasis Market Size by Country
9.2.1 Asia-Pacific Biologic Medications for Psoriasis Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Biologic Medications for Psoriasis Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Biologic Medications for Psoriasis Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Biologic Medications for Psoriasis Sales by Country
10.1.1 South America Biologic Medications for Psoriasis Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Biologic Medications for Psoriasis Sales by Country (2020-2025)
10.1.3 South America Biologic Medications for Psoriasis Sales Forecast by Country (2026-2031)
10.2 South America Biologic Medications for Psoriasis Market Size by Country
10.2.1 South America Biologic Medications for Psoriasis Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Biologic Medications for Psoriasis Market Size by Country (2020-2025)
10.2.3 South America Biologic Medications for Psoriasis Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Biologic Medications for Psoriasis Sales by Country
11.1.1 Middle East and Africa Biologic Medications for Psoriasis Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Biologic Medications for Psoriasis Sales by Country (2020-2025)
11.1.3 Middle East and Africa Biologic Medications for Psoriasis Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Biologic Medications for Psoriasis Market Size by Country
11.2.1 Middle East and Africa Biologic Medications for Psoriasis Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Biologic Medications for Psoriasis Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Biologic Medications for Psoriasis Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Biologic Medications for Psoriasis Value Chain Analysis
12.1.1 Biologic Medications for Psoriasis Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Biologic Medications for Psoriasis Production Mode & Process
12.2 Biologic Medications for Psoriasis Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Biologic Medications for Psoriasis Distributors
12.2.3 Biologic Medications for Psoriasis Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.